Pharmazz’s PMZ-1620 could become the first-in-class therapy to treat cerebral ischemic stroke, the company said in a statement, through an endothelin (ETB receptor) based mechanism of action, of anti-apoptosis and stimulation of hidden stem cells to repair the damaged brain by formation of new neurons and blood vessels.
Pharmazz, Inc., on Thursday announced that data from the Phase 2 clinical study in patients with acute cerebral ischemic stroke, saying that PMZ-1620 treatment did not have any significant effect on systemic hemodynamics, biochemical or hematological parameters.
No drug related adverse event was reported, the company said adding that full data will be available mid-April this year and will be submitted for publication in a peer-reviewed medical journal.